Precigen Past Earnings Performance

Past criteria checks 0/6

Precigen has been growing earnings at an average annual rate of 36.2%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been declining at an average rate of 46.9% per year.

Key information

36.2%

Earnings growth rate

47.2%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	-46.9%
Return on equity	-80.9%
Net Margin	-1,540.6%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31

Broker Revenue Forecasts For Precigen, Inc. (NASDAQ:PGEN) Are Surging Higher

Aug 12

Precigen (NASDAQ:PGEN) Is Carrying A Fair Bit Of Debt

Jul 16

Time To Worry? Analysts Are Downgrading Their Precigen, Inc. (NASDAQ:PGEN) Outlook

Mar 03

What Kind Of Investors Own Most Of Precigen, Inc. (NASDAQ:PGEN)?

Feb 12

Precigen announces positive preliminary data from early-stage PRGN-2009 cancer study

Jan 13

Revenue & Expenses Breakdown
Beta

How Precigen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:PGEN Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	6	-96	40	0
30 Sep 23	7	-85	42	0
30 Jun 23	22	-73	43	0
31 Mar 23	23	-79	46	0
31 Dec 22	27	-80	48	0
30 Sep 22	29	-84	48	0
30 Jun 22	15	-103	49	23
31 Mar 22	16	-108	51	0
31 Dec 21	14	-111	52	0
30 Sep 21	30	-124	71	0
30 Jun 21	50	-125	82	0
31 Mar 21	77	-110	85	0
31 Dec 20	32	-104	73	0
30 Sep 20	101	-100	88	0
30 Jun 20	96	-122	88	0
31 Mar 20	98	-138	89	0
31 Dec 19	91	-169	99	0
30 Sep 19	108	-373	85	0
30 Jun 19	122	-381	102	0
31 Mar 19	134	-414	117	0
31 Dec 18	151	-375	125	0
30 Sep 18	194	-196	148	0
30 Jun 18	208	-179	148	0
31 Mar 18	217	-132	153	0
31 Dec 17	219	-71	130	0
30 Sep 17	200	-134	148	0
30 Jun 17	203	-123	143	0
31 Mar 17	201	-154	134	0
31 Dec 16	191	-187	138	0
30 Sep 16	186	-175	137	0
30 Jun 16	191	-184	125	0
31 Mar 16	183	-176	118	0
31 Dec 15	174	-84	107	0
30 Sep 15	163	-33	92	0
30 Jun 15	131	-47	85	0
31 Mar 15	98	-59	76	0
31 Dec 14	72	-82	63	0
30 Sep 14	48	-113	53	0
30 Jun 14	33	-52	46	0
31 Mar 14	28	-11	39	0
31 Dec 13	24	-57	33	0
30 Sep 13	23	-82	26	0
30 Jun 13	20	-116	24	0

Quality Earnings: PGEN is currently unprofitable.

Growing Profit Margin: PGEN is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 36.2% per year.

Accelerating Growth: Unable to compare PGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).

Return on Equity

High ROE: PGEN has a negative Return on Equity (-80.93%), as it is currently unprofitable.

Precigen Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Independent Director recently sold US$136k worth of stock

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Independent Director recently bought US$688k worth of stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

President exercised options and sold US$58k worth of stock

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Price target increased to US$14.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Precigen names Rutul Shah as chief operating officer

Chief Financial Officer recently bought US$51k worth of stock

Circling Back On Precigen

Independent Director recently sold US$115k worth of stock

Consensus revenue estimates fall by 66%

Independent Director notifies of intention to sell stock

Price target decreased to US$12.00

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen Q2 2022 Earnings Preview

Price target increased to US$13.75

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

Precigen to sell Trans Ova Genetics for $170M upfront

President exercised options and sold US$211k worth of stock

Consensus revenue estimates increase by 21%

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022

Precigen, Inc. to Report Q1, 2022 Results on May 09, 2022

Precigen, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Precigen, Inc. Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Consensus estimates of losses per share improve by 14%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Precigen, Inc. to Report Q4, 2021 Results on Mar 01, 2022

The Prognosis On Precigen

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Precigen, Inc Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia

Insufficient new directors

Revenue & Expenses Breakdown
Beta